Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice - PubMed (original) (raw)
. 2010 Aug;62(8):2283-93.
doi: 10.1002/art.27536.
Martin Hegen, Elizabeth Quadros, Cheryl L Nickerson-Nutter, Kenneth C Appell, Andrew G Cole, Yuefei Shao, Steve Tam, Michael Ohlmeyer, Bojing Wang, Debra G Goodwin, Earl F Kimble, Jorge Quintero, Min Gao, Peter Symanowicz, Christopher Wrocklage, Jennifer Lussier, Scott H Schelling, Amha G Hewet, Dejun Xuan, Rustem Krykbaev, Jenny Togias, Xin Xu, Richard Harrison, Tarek Mansour, Mary Collins, James D Clark, Maria L Webb, Katherine J Seidl
Affiliations
- PMID: 20506481
- DOI: 10.1002/art.27536
Free article
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice
Tsung H Lin et al. Arthritis Rheum. 2010 Aug.
Free article
Abstract
Objective: All gamma-chain cytokines signal through JAK-3 and JAK-1 acting in tandem. We undertook this study to determine whether the JAK-3 selective inhibitor WYE-151650 would be sufficient to disrupt cytokine signaling and to ameliorate autoimmune disease pathology without inhibiting other pathways mediated by JAK-1, JAK-2, and Tyk-2.
Methods: JAK-3 kinase selective compounds were characterized by kinase assay and JAK-3-dependent (interleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF]) cell-based assays measuring proliferation or STAT phosphorylation. In vivo, off-target signaling was measured by IL-22- and erythropoietin (EPO)-mediated models, while on-target signaling was measured by IL-2-mediated signaling. Efficacy of JAK-3 inhibitors was determined using delayed-type hypersensitivity (DTH) and collagen-induced arthritis (CIA) models in mice.
Results: In vitro, WYE-151650 potently suppressed IL-2-induced STAT-5 phosphorylation and cell proliferation, while exhibiting 10-29-fold less activity against JAK-3-independent IL-6- or GM-CSF-induced STAT phosphorylation. Ex vivo, WYE-151650 suppressed IL-2-induced STAT phosphorylation, but not IL-6-induced STAT phosphorylation, as measured in whole blood. In vivo, WYE-151650 inhibited JAK-3-mediated IL-2-induced interferon-gamma production and decreased the natural killer cell population in mice, while not affecting IL-22-induced serum amyloid A production or EPO-induced reticulocytosis. WYE-151650 was efficacious in mouse DTH and CIA models.
Conclusion: In vitro, ex vivo, and in vivo assays demonstrate that WYE-151650 is efficacious in mouse CIA despite JAK-3 selectivity. These data question the need to broadly inhibit JAK-1-, JAK-2-, or Tyk-2-dependent cytokine pathways for efficacy.
Similar articles
- Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A, Arai K. Yoshimura A, et al. Oncologist. 1996;1(5):337-339. Oncologist. 1996. PMID: 10388012 - Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5.
Yamaguchi T, Kimura H, Kurabayashi M, Kozawa K, Kato M. Yamaguchi T, et al. Immunol Lett. 2008 Jun 15;118(1):88-95. doi: 10.1016/j.imlet.2008.03.005. Epub 2008 Apr 10. Immunol Lett. 2008. PMID: 18440651 - Human and rodent pancreatic beta-cells express IL-4 receptors and IL-4 protects against beta-cell apoptosis by activation of the PI3K and JAK/STAT pathways.
Kaminski A, Welters HJ, Kaminski ER, Morgan NG. Kaminski A, et al. Biosci Rep. 2009 Dec 15;30(3):169-75. doi: 10.1042/BSR20090021. Biosci Rep. 2009. PMID: 19531027 - JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA. Waldmann TA. Mol Cell Endocrinol. 2017 Aug 15;451:66-70. doi: 10.1016/j.mce.2017.02.019. Epub 2017 Feb 15. Mol Cell Endocrinol. 2017. PMID: 28214593 Free PMC article. Review. - Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway.
Malemud CJ. Malemud CJ. Pharmaceuticals (Basel). 2010 May 12;3(5):1446-1455. doi: 10.3390/ph3051446. Pharmaceuticals (Basel). 2010. PMID: 27713312 Free PMC article. Review.
Cited by
- JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.
O'Shea JJ, Plenge R. O'Shea JJ, et al. Immunity. 2012 Apr 20;36(4):542-50. doi: 10.1016/j.immuni.2012.03.014. Immunity. 2012. PMID: 22520847 Free PMC article. Review. - Are peptides a solution for the treatment of hyperactivated JAK3 pathways?
Dullius A, Rocha CM, Laufer S, de Souza CFV, Goettert MI. Dullius A, et al. Inflammopharmacology. 2019 Jun;27(3):433-452. doi: 10.1007/s10787-019-00589-2. Epub 2019 Mar 30. Inflammopharmacology. 2019. PMID: 30929155 Review. - Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, Sakai T, Nakamura M, Motokawa S, Nakamura T, Kawakami A. Migita K, et al. Clin Exp Immunol. 2014 Feb;175(2):208-14. doi: 10.1111/cei.12234. Clin Exp Immunol. 2014. PMID: 24665995 Free PMC article. Clinical Trial. - Advances in rheumatoid arthritis animal models.
Moudgil KD, Kim P, Brahn E. Moudgil KD, et al. Curr Rheumatol Rep. 2011 Oct;13(5):456-63. doi: 10.1007/s11926-011-0200-z. Curr Rheumatol Rep. 2011. PMID: 21792748 Free PMC article. - Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice.
DeMars KM, Pacheco SC, Yang C, Siwarski DM, Candelario-Jalil E. DeMars KM, et al. Front Neurol. 2017 Jul 25;8:363. doi: 10.3389/fneur.2017.00363. eCollection 2017. Front Neurol. 2017. PMID: 28790974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous